C21 · Pharmaceuticals · China
Drug approval applications completed under priority review
China: 110 in 2024.
- 110 Latest · China · 2024
- Annual Release cadence
- 2 Records · 1 region · 2024
Verified 17 Sep 2026 · 2 publishers · Next period 2025
The figure
One published observation so far. A chart follows as soon as a second period is published.
Drug approval applications completed under priority review
China, 2024
Every record
2 records · 1 region · 2024. Each period links to its record: the value, its source evidence and original document.
| Period | Value | Source | Type |
|---|---|---|---|
| China 2 records | |||
| 2024 | 110 | State Council · 31 Dec 2024 | |
| 2024 | 110 | NMPA · 31 Dec 2024 | |
Download this data
Every file carries its provenance: the CSV has a source column per row, and the chart images print the publisher, the licence and this page's address under the drawing. Source: State Council and NMPA. Licence: CC BY 4.0.
Use and publication rights
- View, cite and link: free
Quote any number, cite this page or a single record, and link to it anywhere.
- Copy, chart and republish: free with attribution
The data is published under CC BY 4.0, commercial use included. Credit StatOrigin and the original publisher (State Council and NMPA); the chart files already carry that line.
- The source documents: the publisher's terms
Figures are facts read from the publishers' own documents. The documents themselves, their text and design, stay under each publisher's terms; follow the source links for those.
How this measure is built
- Definition
- Total number of drug approval applications completed under an expedited priority review pathway.
- Measure
- One slice of Drug approval applications ( counting rule: completed, form: count, segment: priority review ) . Total number of regulatory applications reviewed for drug marketing authorization. Region and period are columns on every record, not slices.
- Limitations
- Values are shown as published; StatOrigin does not revise, fill gaps or convert currencies.
- Verification
- Each value, unit, period and place was checked against its source evidence before publication. See the methodology and the corrections process.
Sources · 2 documents
| Document | Publisher | Published | Data points |
|---|---|---|---|
| Measures facilitate approval of 48 first-in-class innovative drugs | NMPA | — | 1 |
| Measures facilitate approval of 48 first-in-class innovative drugs | State Council | — | 1 |
Other slices of drug approval applications
- Priority review drug approval applications completed growth rate 2 priority review
- Approved drug marketing registration applications (half year) 1 approved
- Share of priority review drug approval applications treating cancer 1 priority review · oncology
Frequently asked questions
What is the latest drug approval applications completed under priority review?
China: 110 in 2024.
Where does this data come from?
From 2 documents published by State Council and NMPA. Every figure on this page links to its record, which preserves the original source evidence.
How often is it updated?
Annual. The newest published period is 2024; the next release should cover 2025. A new figure appears here once the publisher releases it and it passes verification.
Can I use this data?
Yes. StatOrigin publishes it under CC BY 4.0: you may copy, chart and republish it, including commercially, with attribution to StatOrigin and to the original publisher.
Cite this page
Cite the page as a data set, or open any record to cite one figure: each record carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.
StatOrigin. (2026). Drug approval applications completed under priority review [Data set]. Retrieved October 28, 2026, from https://statorigin.org/indicators/drug-approval-applications-completed-under-priority-review
"Drug approval applications completed under priority review." StatOrigin, 2026, https://statorigin.org/indicators/drug-approval-applications-completed-under-priority-review. Accessed 28 Oct. 2026.
StatOrigin. "Drug approval applications completed under priority review." Data set, 2026. Accessed October 28, 2026. https://statorigin.org/indicators/drug-approval-applications-completed-under-priority-review.
@misc{statorigin_drug_approval_applications_completed_under_priority_review_2026, title = {Drug approval applications completed under priority review}, author = {{StatOrigin}}, year = {2026}, url = {https://statorigin.org/indicators/drug-approval-applications-completed-under-priority-review}, note = {Data set. Accessed 2026-10-28} }